MSH2 and prostate carcinoma: MMR protein loss in line with the underlying MMR gene mutation was identified in 11/16 prostate cancers, including all MSH2 and MSH6 mutant tumors and supports observations of a high degree, 69–100 %, of MMR deficiency in prostate cancers in Lynch syndrome [8, 24, 27].